首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1517506

重組蛋白的全球市場

Global Recombinant Proteins Market

出版日期: 2024年06月14日 | 出版商:

BCC Research | 英文 108 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球重組蛋白市場規模預計將從 2023 年的 1,324 億美元增至 2029 年的 2,036 億美元，預測期內複合年成長率為 7.5%。

北美地區預計將從2023年的502億美元成長到2029年的743億美元，複合年成長率為6.7%。此外，亞太地區預計將從2023年的303億美元成長到2029年的507億美元，複合年成長率為9.2%。

本報告調查了全球重組蛋白市場，並提供了市場概況、市場影響因素和市場機會分析、新興技術和技術發展趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析，總結了競爭格局，主要企業簡介等

細分細分
全球重組蛋白市場：依產品類型
荷爾蒙
市場規模/預測
細胞激素
市場規模/預測
酵素
市場規模/預測
抗體
市場規模/預測
抗原
市場規模/預測
其他
市場規模/預測
全球重組蛋白市場：依宿主細胞類型
細菌宿主細胞
市場規模/預測
酵母菌和真菌細胞
市場規模/預測
哺乳動物細胞
市場規模/預測
昆蟲細胞
市場規模/預測
其他
市場規模/預測
全球重組蛋白市場：依應用分類
治療方法和疫苗
市場規模/預測
生物醫學研究
市場規模/預測
診斷
市場規模/預測
地域分佈
全球重組蛋白市場：按地區
北美洲
歐洲
亞太地區
其他地區

第6章競爭訊息

競爭格局
併購分析
臨床試驗活動

第7章重組蛋白市場的 ESG觀點

重組蛋白市場的永續性
了解 ESG資料
環保性能
社會表現
管治績效
BCC的結語

第8章附錄

調查方法
來源
縮寫詞
公司簡介
AMGEN INC.
BAYER AG
F. HOFFMANN-LA ROCHE LTD.
LILLY
MERCK KGAA
NOVO NORDISK A/S
PFIZER INC.
SANDOZ GROUP AG
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.

簡介目錄圖表

Product Code: BIO254A

The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.

The North American market for recombinant proteins is estimated to increase from $50.2 billion in 2023 to reach $74.3 billion by 2029, at a CAGR of 6.7% from 2024 through 2029.

The Asia-Pacific market for recombinant proteins is estimated to increase from $30.3 billion in 2023 to reach $50.7 billion by 2029, at a CAGR of 9.2% from 2024 through 2029.

Report Scope

This report covers the current and future global market for recombinant proteins, including a detailed analysis of the market's drivers, restraints and opportunities. The report also covers market projections for 2029, the market's competitive environment and companies' pipeline activities. The report delivers market estimates and forecasts for recombinant proteins categorized according to product type, host cell type, application, and region. Based on product type the market is segmented into hormones, cytokines, enzymes, antigens, antibodies, and others. Based on the host cell type, recombinant proteins are categorized as mammalian, insect, yeast and fungi, bacterial, and other cell types. The market is segmented by application into therapeutics and vaccines, biomedical research, and diagnostics. The report includes the company profiles of the key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover proteins produced through hybridoma techniques. The report also excludes COVID-19 vaccines based on recombinant technology.

By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Regional analysis is further broken down by country as follows: North America-the U.S. and Canada; Europe-Germany, the U.K., France, Italy, and the Rest of Europe; Asia-Pacific-China, Japan, India, and the Rest of Asia-Pacific. For market estimates, data have been provided for 2021 and 2022 as the historic years, 2023 as the base year, and a forecast through 2029.

Report Includes

45 data tables and 46 additional tables
Analysis of the global market for recombinant proteins
Analyses of the global market trends, with market revenue data for 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
Discussion of the market drivers, restraints and opportunities
Estimate of the current market size and revenue prospects, along with a market share analysis by product (protein type), host cell type, application and region
Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario, and the expected impact of macroeconomic factors
Overview of sustainability and ESG trends, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
Analysis of recent patents and pipeline activity
A look at the industry structure, including companies' market shares, M&A activity and venture funding
Company profiles of major players within the industry, including Novo Nordisk A/S, Lilly, Sanofi, and Amgen Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Types of Expression Host Systems
Mechanism of Action of Recombinant Proteins
Agonists
Antagonists
Common Steps Involved in Recombinant Protein Production

Chapter 3 Market Dynamics

Drivers
Growing R&D Investments in Biopharmaceuticals
Increasing Demand for Non-Hybridoma Techniques
Restraints
High Production Costs
Post-Translational Modifications and Protein Stability
Opportunities
Diagnostic and Therapeutic Applications of Recombinant Antibodies
Continuous Manufacturing and Improving Product Yields

Chapter 4 Emerging Technologies and Developments

Overview
Emerging Technologies
Protein-Engineering Advances
CRISPR Genome Editing
Cell-Free Protein Synthesis

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Global Market for Recombinant Proteins, by Product Type
Hormones
Market Size and Forecast
Cytokines
Market Size and Forecast
Enzymes
Market Size and Forecast
Antibodies
Market Size and Forecast
Antigens
Market Size and Forecast
Others
Market Size and Forecast
Global Market for Recombinant Proteins, by Host Cell Type
Bacterial Host Cells
Market Size and Forecast
Yeast and Fungi Cells
Market Size and Forecast
Mammalian Cells
Market Size and Forecast
Insect Cells
Market Size and Forecast
Other Cells
Market Size and Forecast
Global Market for Recombinant Proteins, by Application
Therapeutics and Vaccines
Market Size and Forecast
Biomedical Research
Market Size and Forecast
Diagnostics
Market Size and Forecast
Geographic Breakdown
Global Market for Recombinant Proteins, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Competitive Landscape
M&A Analysis
Clinical Trial Activities

Chapter 7 ESG Perspective in the Recombinant Proteins Market

Sustainability in the Recombinant Proteins Market
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC

Chapter 8 Appendix

Methodology
Sources
Acronyms
Company Profiles
AMGEN INC.
BAYER AG
F. HOFFMANN-LA ROCHE LTD.
LILLY
MERCK KGAA
NOVO NORDISK A/S
PFIZER INC.
SANDOZ GROUP AG
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.

簡介目錄圖表

List of Tables

Summary Table : Global Market for Recombinant Proteins, by Region, Through 2029
Table 1 : Comparison of Different Protein Expression Host Systems
Table 2 : R&D Expenditures of Key Biopharmaceutical Companies, 2023
Table 3 : Global Market for Recombinant Proteins, by Product Type, Through 2029
Table 4 : Global Market for Recombinant Hormone Proteins, by Region, Through 2029
Table 5 : Global Market for Recombinant Cytokine Proteins, by Region, Through 2029
Table 6 : Global Market for Recombinant Enzyme Proteins, by Region, Through 2029
Table 7 : Global Market for Recombinant Antibody Proteins, by Region, Through 2029
Table 8 : Global Market for Recombinant Antigen Proteins, by Region, Through 2029
Table 9 : Global Patient Population Diagnosed with Bleeding Disorders
Table 10 : Global Market for Other Recombinant Proteins, by Region, Through 2029
Table 11 : Global Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 12 : Global Market for Recombinant Proteins from Bacterial Host Cells, by Region, Through 2029
Table 13 : Global Market for Recombinant Proteins from Yeast and Fungi Host Cells, by Region, Through 2029
Table 14 : Global Market for Recombinant Proteins from Mammalian Host Cells, by Region, Through 2029
Table 15 : Global Market for Recombinant Proteins from Insect Host Cells, by Region, Through 2029
Table 16 : Global Market for Recombinant Proteins from Other Host Cells, by Region, Through 2029
Table 17 : Global Market for Recombinant Proteins, by Application, Through 2029
Table 18 : Therapeutic Applications of Recombinant Proteins, by Product Type
Table 19 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, by Region, Through 2029
Table 20 : Global Market for Recombinant Proteins for Biomedical Research, by Region, Through 2029
Table 21 : Global Market for Recombinant Proteins for Diagnostics, by Region, Through 2029
Table 22 : Global Market for Recombinant Proteins, by Region, Through 2029
Table 23 : North American Market for Recombinant Proteins, by Product Type, Through 2029
Table 24 : North American Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 25 : North American Market for Recombinant Proteins, by Application, Through 2029
Table 26 : North American Market for Recombinant Proteins, by Country, Through 2029
Table 27 : European Market for Recombinant Proteins, by Product Type, Through 2029
Table 28 : European Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 29 : European Market for Recombinant Proteins, by Application, Through 2029
Table 30 : European Market for Recombinant Proteins, by Country, Through 2029
Table 31 : Asia-Pacific Market for Recombinant Proteins, by Product Type, Through 2029
Table 32 : Asia-Pacific Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 33 : Asia-Pacific Market for Recombinant Proteins, by Application, Through 2029
Table 34 : Asia-Pacific Market for Recombinant Proteins, by Country, Through 2029
Table 35 : RoW Market for Recombinant Proteins, by Product Type, Through 2029
Table 36 : RoW Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 37 : RoW Market for Recombinant Proteins, by Application, Through 2029
Table 38 : Top Recombinant Protein Drug Developers, 2023
Table 39 : Major Strategic Alliances in the Recombinant Proteins Industry, 2022-2024
Table 40 : Technology Driven Partnerships and Acquisitions in the Recombinant Protein Industry, 2023
Table 41 : Select Recombinant Protein Therapeutics in Phase 3 Clinical Trials, 2023
Table 42 : Recombinant Protein Therapeutics in Phase 1 and 2 Clinical Trials, 2023
Table 43 : Recombinant Protein Therapeutics in Phase 4 and Observational Clinical Trials, 2023
Table 44 : Select Active Patents of Key Companies, 2020-2023
Table 45 : ESG Rankings for Major Recombinant Protein Drug Companies, 2023*
Table 46 : ESG: Environmental Overview
Table 47 : ESG: Social Factors Overview
Table 48 : ESG: Governance Overview
Table 49 : Report Sources
Table 50 : Glossary of Terms Used in the Recombinant Proteins Market
Table 51 : Amgen Inc.: Company Snapshot
Table 52 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 53 : Amgen Inc.: Product Portfolio
Table 54 : Amgen Inc.: News/Key Developments, 2022 and 2023
Table 55 : Bayer AG: Company Snapshot
Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 57 : Bayer AG: Product Portfolio
Table 58 : Bayer AG: News/Key Developments, 2023
Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 61 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 62 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 63 : Lilly: Company Snapshot
Table 64 : Lilly: Financial Performance, FY 2022 and 2023
Table 65 : Lilly: Product Portfolio
Table 66 : Lilly: News/Key Developments, 2023
Table 67 : Merck KGaA: Company Snapshot
Table 68 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 69 : Merck KGaA: Product Portfolio
Table 70 : Merck KGaA: News/Key Developments, 2022 and 2023
Table 71 : Novo Nordisk A/S: Company Snapshot
Table 72 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 73 : Novo Nordisk A/S: Product Portfolio
Table 74 : Novo Nordisk A/S: News/Key Developments, 2023 and 2024
Table 75 : Pfizer Inc.: Company Snapshot
Table 76 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Pfizer Inc.: Product Portfolio
Table 78 : Pfizer Inc.: News/Key Developments, 2023
Table 79 : Sandoz Group AG: Company Snapshot
Table 80 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 81 : Sandoz Group AG: Product Portfolio
Table 82 : Sandoz Group AG: News/Key Developments, 2023
Table 83 : Sanofi: Company Snapshot
Table 84 : Sanofi: Financial Performance, FY 2022 and 2023
Table 85 : Sanofi: Product Portfolio
Table 86 : Sanofi: News/Key Developments, 2022-2024
Table 87 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 88 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022
Table 89 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 90 : Takeda Pharmaceutical Co. Ltd.: Key Developments, 2022 and 2023

List of Figures

Summary Figure : Global Market Shares of Recombinant Proteins, by Region, 2023
Figure 1 : Basic Steps Involved in Recombinant Protein Production
Figure 2 : Market Dynamics of Recombinant Proteins
Figure 3 : Global Biopharmaceutical R&D Expenditures, 2020-2026
Figure 4 : Applications of Recombinant Antibodies
Figure 5 : Advantages and Disadvantages of Continuous Manufacturing
Figure 6 : Global Market Shares of Recombinant Proteins, by Product Type, 2023
Figure 7 : Global Market for Recombinant Hormone Proteins, 2021-2029
Figure 8 : Global Market for Recombinant Hormone Proteins, by Region, 2021-2029
Figure 9 : Global Market for Recombinant Cytokine Proteins, 2021-2029
Figure 10 : Global Market for Recombinant Cytokine Proteins, by Region, 2021-2029
Figure 11 : Global Market for Recombinant Enzyme Proteins, 2021-2029
Figure 12 : Global Market for Recombinant Enzyme Proteins, by Region, 2021-2029
Figure 13 : Advantages of Recombinant Antibodies
Figure 14 : Global Market for Recombinant Antibody Proteins, 2021-2029
Figure 15 : Global Market for Recombinant Antibody Proteins, by Region, 2021-2029
Figure 16 : Global Market for Recombinant Antigen Proteins, 2021-2029
Figure 17 : Global Market for Recombinant Antigen Proteins, by Region, 2021-2029
Figure 18 : Global Market for Other Recombinant Proteins, 2021-2029
Figure 19 : Global Market for Other Recombinant Proteins, by Region, 2021-2029
Figure 20 : Global Market Shares of Recombinant Proteins, by Host Cell Type, 2023
Figure 21 : Global Market for Recombinant Proteins from Bacterial Host Cells, 2021-2029
Figure 22 : Global Market for Recombinant Proteins from Yeast and Fungi Host Cells, 2021-2029
Figure 23 : Global Market for Recombinant Proteins from Mammalian Host Cells, 2021-2029
Figure 24 : Global Market for Recombinant Proteins from Insect Host Cells, 2021-2029
Figure 25 : Global Market for Recombinant Proteins from Other Host Cells, 2021-2029
Figure 26 : Global Market Shares of Recombinant Proteins, by Application, 2023
Figure 27 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, 2021-2029
Figure 28 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, by Region, 2021-2029
Figure 29 : Global Market for Recombinant Proteins for Biomedical Research, 2021-2029
Figure 30 : Global Market for Recombinant Proteins for Biomedical Research, by Region, 2021-2029
Figure 31 : Global Market for Recombinant Proteins for Diagnostics, 2021-2029
Figure 32 : Global Market for Recombinant Proteins for Diagnostics, by Region, 2021-2029
Figure 33 : Global Market for Recombinant Proteins, by Region, 2021-2029
Figure 34 : North American Market Shares of Recombinant Proteins, by Country, 2023
Figure 35 : European Market Shares of Recombinant Proteins, by Country, 2023
Figure 36 : Asia-Pacific Market Shares of Recombinant Proteins, by Country, 2023
Figure 37 : Key ESG Metrics of Recombinant Protein Companies
Figure 38 : Amgen Inc.: Revenue Shares, by Product, FY 2023
Figure 39 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 40 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 41 : Bayer AG: Revenue Shares, by Country/Region, FY 2023
Figure 42 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 43 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 44 : Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 45 : Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 46 : Merck KGaA: Revenue Shares, by Business Unit, FY 2023
Figure 47 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
Figure 48 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
Figure 49 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 51 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 52 : Sandoz Group AG: Revenue Shares, by Business Unit, FY 2023
Figure 53 : Sandoz Group AG: Revenue Shares, by Country/Region, FY 2023
Figure 54 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 55 : Sanofi: Revenue Shares, by Country/ Region, FY 2023
Figure 56 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2022
Figure 57 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022